New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
05:55 EDTVSTM, VSTM, ONCY, ONCY, RIGL, RIGL, CELG, CELG, OXBT, OXBT, GALE, GALE, GTXI, GTXI, AFFY, AFFYBiotech Industry Organization to host a conference
15th Annual BIO CEO & Investor Conference is being held in New York on February 11-12.
News For CELG;OXBT;GALE;GTXI;AFFY;VSTM;ONCY;RIGL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
07:12 EDTCELGWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
August 27, 2015
16:03 EDTCELGCelgene completes acquisition of Receptos
Subscribe for More Information
08:28 EDTVSTMVerastem weakness overdone, says JMP Securities
After Verastem reported that 24% of the KRAS-mutated NSCLC patients in a study of its FAK inhibitor defactinib had experienced serious adverse events, JMP Securities notes that it did not ascribe any valuation for the drug as a treatment for this indication. Moreover, the firm does not believe that the study affects the outlook for the drug in other settings, and it says that, given the patients' late stage status, deaths among the participants "would not be seen as an anamoly." JMP adds that the drug met its primary endpoint in the study. JMP reiterates a $23 price target and Outperform rating on the shares.
06:34 EDTONCYOncolytics to present survival data from lung cancer candidate reolysin
Subscribe for More Information
August 26, 2015
16:26 EDTVSTMOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
15:16 EDTVSTMVerastem says VS-6063 results under embargo, believes study has met goals
Verastem issued the following statement in response to inquiries regarding the anticipated oral presentation of VS-6063 data from a Phase 2 study in patients with KRAS mutant non-small cell lung cancer, or NSCLC, at the 16th World Conference on Lung Cancer: "While updated results from the Phase 2 study of VS-6063 in KRAS mutant non-small cell lung cancer are under embargo until WCLC, Verastem believes the study has met its goals, with encouraging outcomes that the company plans to explore in future studies. The population explored in this study has refractory, advanced lung cancer, with a median of three prior therapies, and as many as eight prior therapies. The advanced stage of disease led, in some cases, to deaths even in the period between screening and prior to first dose of VS-6063. Two subjects reported as having grade 5 respiratory failure were on multiple concomitant medications and presented with multiple co-morbidities. Both were thoroughly evaluated and reported to the regulatory authorities in 2013 and 2014 when they occurred. The totality of safety and efficacy data seen to date with VS-6063 across multiple clinical trials, multiple tumor types and stages of treatment is promising. In addition, in the company's registration-directed COMMAND trial in mesothelioma, an independent data safety monitoring board has met and reviewed study data, including adverse events, three times and recommended no changes to study protocol. There have been over 300 patients treated to date with VS-6063, including patients on drug for more than one year. Verastem remains encouraged by the clinical potential of targeting cancer stem cells through FAK inhibition, and is unwavering in its commitment to delivering novel, safe and effective treatments to patients with unmet medical needs."
11:55 EDTVSTMVerastem safety concerns on NSCLC data misplaced, says Mizuho
Subscribe for More Information
11:43 EDTVSTMVerastem selloff on 'placeholder' abstract ignores key driver, says Roth Capital
Subscribe for More Information
10:51 EDTVSTMVerastem shares defended at Roth Capital
Subscribe for More Information
09:24 EDTVSTMVerastem to present data at World Conference on Lung Cancer
Subscribe for More Information
06:33 EDTONCYOncolytics completes enrollment in Phase II lung cancer study of Reolysin
Subscribe for More Information
06:32 EDTONCYOncolytics completes enrollment in Reolysin Phase II study
Oncolytics Biotech announced that enrollment has been completed in a randomized Phase II study of Reolysin in patients with previously treated advanced or metastatic non-small cell lung cancer, or NSCLC. The trial is being sponsored and conducted by the NCIC Clinical Trials Group, or NCIC CTG, at Queen's University in Kingston, Ontario. The primary objective of the trial is to evaluate the effect of Reolysin in combination with standard salvage chemotherapy on the progression free survival of patients with advanced or metastatic non-small cell lung cancer. The secondary objectives are to determine the tolerability and toxicity of the therapeutic combination; to investigate additional potential measures of efficacy, including progression rates at three months, objective response rate and overall survival; and to explore potential molecular factors predictive of response. Although accrual is complete, patient follow-up will continue until planned analyses have been conducted.
August 25, 2015
07:31 EDTCELGCelgene announces expiration of tender offer for Receptos shares
Subscribe for More Information
August 24, 2015
18:55 EDTCELGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTCELGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
13:36 EDTCELGBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
07:07 EDTGALEIDMC recommends reduction of cardiac toxicity monitoring in Galena NeuVax trial
Galena Biopharma announced that the Independent Data Monitoring Committee, or IDMC, has recommended to the company that it can reduce the cardiac toxicity monitoring for patients in its NeuVax Phase 3 Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment, or PRESENT, clinical trial. The trial is being run under a Special Protocol Assessment, or SPA, approved by the FDA. Following its most recent IDMC meeting in June, the IDMC recommended routine cardiac monitoring could be reduced in the PRESENT trial and that such a reduction is justified and consistent with the pre-specified Cardiac Toxicity Monitoring Stopping Rules defined in the study protocol. The IDMC concluded that cardiac toxicity monitoring by echocardiogram, or ECHO, or multiple-gated acquisition, or MUGA, scans could be reduced. The IDMC had no other suggestions and recommended the trial continue as planned.
August 23, 2015
12:35 EDTCELGBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 20, 2015
05:48 EDTVSTMMizuho keeps TESARO, Verastem, OncoMed as top biotech picks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use